PLUS1
4.25
0.33 (8.42%)
0.33 (8.42%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Genprex Inc | GNPX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.33 | 8.42% | 4.25 | 19:27:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.97 | 3.816 | 4.30 | 4.24 | 3.92 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 4.18 | 4.24 | 0.06 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,679 | 2,240,150 | $ 4.09 | $ 9,164,564 | 1,738,390 | 1.10 - 7.03 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:27:03 | 50 | $ 4.24 | USD |
Genprex Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 182.98M | 43.05M | 38.58M | $ - | $ - | -0.66 | -7.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Genprex News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/21/2021 | 08:30 | Business Wire | Genprex to Present its Cutting-Edge Gene Therapies at the.. |
| 1/14/2021 | 08:30 | Business Wire | Genprex to Present at NobleCon17 on January 19 |
| 1/13/2021 | 09:00 | Business Wire | Genprex Achieves Major Manufacturing Milestone for REQORSAâ˘.. |
| 1/04/2021 | 11:35 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 12/24/2020 | 13:02 | Business Wire | Genprex, Inc. Announces Closing Of $12 Million Registered.. |
| 12/22/2020 | 13:15 | Business Wire | Genprex, Inc. Announces $12 Million Registered Direct.. |
| 12/22/2020 | 09:32 | Business Wire | Genprex Completes Manufacturing Scale-Up for Clinical-Grade.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.78 | 4.30 | 3.65 | 3.87 | 1,087,289 | 0.47 | 12.43% |
| 1 Month | 5.07 | 5.10 | 3.51 | 4.04 | 1,384,060 | -0.82 | -16.17% |
| 3 Months | 3.29 | 5.72 | 2.95 | 4.02 | 1,225,694 | 0.96 | 29.18% |
| 6 Months | 3.58 | 5.72 | 2.84 | 3.88 | 1,050,422 | 0.67 | 18.72% |
| 1 Year | 1.12 | 7.03 | 1.10 | 3.54 | 2,724,550 | 3.13 | 279.46% |
| 3 Years | 4.69 | 19.4499 | 0.231 | 3.25 | 1,261,167 | -0.44 | -9.38% |
| 5 Years | 4.69 | 19.4499 | 0.231 | 3.25 | 1,261,167 | -0.44 | -9.38% |
Genprex Description
| Genprex Inc is a clinical stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells. |
